BidaskClub upgraded shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from a buy rating to a strong-buy rating in a research note published on Thursday morning.
Several other research analysts also recently issued reports on the stock. B. Riley started coverage on shares of Deciphera Pharmaceuticals in a report on Friday, February 16th. They set a buy rating and a $43.00 price objective on the stock. Zacks Investment Research upgraded shares of Deciphera Pharmaceuticals from a hold rating to a buy rating and set a $22.00 price objective on the stock in a report on Monday, December 25th. One analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating to the company. Deciphera Pharmaceuticals currently has a consensus rating of Buy and an average price target of $41.14.
Shares of NASDAQ:DCPH traded down $0.30 on Thursday, hitting $26.75. 2,752 shares of the company were exchanged, compared to its average volume of 164,454. Deciphera Pharmaceuticals has a one year low of $15.15 and a one year high of $29.98. The company has a debt-to-equity ratio of 0.01, a quick ratio of 14.35 and a current ratio of 14.35.
Several institutional investors have recently modified their holdings of the company. Millennium Management LLC boosted its position in shares of Deciphera Pharmaceuticals by 5.9% during the 4th quarter. Millennium Management LLC now owns 728,583 shares of the company’s stock valued at $16,517,000 after acquiring an additional 40,352 shares in the last quarter. TIAA CREF Investment Management LLC acquired a new stake in shares of Deciphera Pharmaceuticals during the 4th quarter valued at about $257,000. Teachers Advisors LLC acquired a new stake in shares of Deciphera Pharmaceuticals during the 4th quarter valued at about $332,000. California State Teachers Retirement System acquired a new stake in shares of Deciphera Pharmaceuticals during the 4th quarter valued at about $295,000. Finally, Deutsche Bank AG acquired a new stake in shares of Deciphera Pharmaceuticals during the 4th quarter valued at about $410,000. Institutional investors and hedge funds own 48.20% of the company’s stock.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company develops DCC-2618, a pan-KIT and pan-PDGFRa inhibitor for the treatment of gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors.
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.